Campos-Nonato I, González A, Barquera S

Language: Spanish
References: 0
Page: 126-136
PDF size: 159.76 Kb.

ABSTRACT

Objective: To assess the association between obesity and insulin resistance with cardiovascular risk factors in the context of epidemiologic transition emphasizing the assessment of Mexican regional differences. Research Design and methods: We use transversal data from Chronic Disease National Survey (n= 2 256), Body Mass Index (BMI) and subrogated measurements of IR were calculated and associated with Diabetes type 2, impaired fasting glucose (IFG), high levels of triglycerides, total cholesterol, LDL, HbA1c, blood pressure and low levels of HDL cholesterol. These associations were assessed by making a gender stratification adjusting by potential confounding. The probability of presence of obesity or IR was estimated by region using multivariate logistic regression. Results: The cardiovascular risk factors were more frequent in obese individuals than ones with normal weight. The obesity and IR contributed independently to high prevalence of the cardiovascular risk factors. From among the Mexican regions, the Northern part of the country had the highest obesity prevalence (23.6%); Mexico City had the highest IR (18%) and metabolic syndrome (17.9%) and the South had the highest plasmatic fasting insulin › 15mU/mL (47.8%). Thus, belonging to the North decreases in a marginal way the possibility of having IR (OR = 2.25, 95%IC = 1.78, 2.85). The obesity in the north was 1.34 times more frequent (95%IC = 1.05 1.71) than the rest of the country. Conclusions: Despite obesity and IR are highly prevalent in the country, there were differences documented that suggest an independent contribution of these factors to the enhancement of chronic diseases. Mexico City and the Southern part have the major prevalence of hyperinsulinism, insulin resistance and metabolic syndrome; these data suggest a major risk for diabetes mellitus type 2. Further investigations are needed to define this process with the possibility of guiding future interventions to prevent non-transmission chronic disease.